Lupin, one of the leading pharmaceutical companies in India, on Friday announced that it has received approval for its Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration, to market a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA. The product will be manufactured at Lupin's facility in Nagpur, India.

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine  betahydroxylase deficiency, and non-diabetic autonomic neuropathy.

Droxidopa Capsules (RLD: Northera) had estimated annual sales of USD 352 million in the U.S., according to IQVIA MAT December 2020 report. 

 Shares of the company declined Rs 27.5, or 2.62%, to settle  at  Rs 1,021.45.  The total volume of shares traded  was  130,906 at  the BSE (Friday).